Hyloris Pharmaceuticals

Hyloris Pharmaceuticals is a specialty biopharmaceutical company headquartered in Liège, Belgium, dedicated to reinventing existing approved medications through innovative reformulations and repurposing to address unmet medical needs. Founded in 2012 by Stijn Van Rompay and Thomas Jacobsen, the company went public on Euronext Brussels in June 2020. Rather than pursuing entirely new chemical entities, Hyloris focuses on complex, patented formulations of established drugs using the FDA's 505(b)(2) regulatory pathway, which is specifically designed for pharmaceuticals where safety and efficacy have already been proven. This approach dramatically reduces development costs, timelines, and risks. The company currently markets three FDA-approved products through partnerships: Maxigesic® IV (non-opioid post-operative pain management), Sotalol IV (atrial fibrillation treatment), and Podofilox Gel (genital wart treatment). As of December 2024, Hyloris operates a portfolio of 24 product candidates at various development stages. Hyloris primarily targets healthcare institutions, hospitals, and specialty pharmacies through a B2B licensing model. The company partners with regional pharmaceutical companies to commercialize products in specific territories, capturing significant royalty and profit-sharing arrangements rather than managing direct sales forces. This asset-light model allows Hyloris to scale without proportional increases in commercial infrastructure. Major partners include Hikma Pharmaceuticals (Maxigesic® IV in the U.S.), AFT Pharmaceuticals (co-development and licensing), and newer partners such as Rosemont Pharmaceuticals, RedHill Biopharma, and companies in emerging markets. The company generates revenue through royalties on partner sales, milestone payments triggered by regulatory approvals and sales achievements, and upfront licensing fees from partnership agreements. In 2024, total revenue and operating income reached €10.0M, up 138% year-over-year, with gross margins exceeding 97%. Hyloris' core competitive advantages center on its systematic application of the 505(b)(2) pathway to complex, high-value pharmaceutical problems. The company applies rigorous selection criteria for new candidates: average R&D investment capped at €7 million per product, development timelines under seven years, and demonstrated unmet medical needs. The portfolio spans diverse therapeutic areas, including cardiovascular disease, pain management, infectious disease, dermatology, and oncology. The company's proprietary patent portfolio protects formulations, processes, and methods of use, creating barriers to generic competition. With a cash position of €23.6 million as of December 31, 2024, zero financial debt, and strong equity of €32.1 million, Hyloris is positioned to self-fund its current pipeline while exploring strategic partnerships for capital-intensive cardiovascular commercialization in the U.S. The company's net operating losses have contracted by 59% year-over-year, approaching breakeven, with a clear pathway to profitability within 2-3 years based on current revenue trajectories and pipeline maturation. Keywords: Pharmaceutical reformulation, 505(b)(2) regulatory pathway, specialty pharmaceuticals, biopharmaceutical licensing, unmet medical needs, non-opioid pain management, cardiovascular disease, pharmaceutical innovation, out-licensing model, pharmaceutical development